Riskpilot← Back to searchSign inGet full accessNORDIC DIAGNOSTICS AS
ASActiveOrg 921765665H0504 Storgata 61, 4307 SandnesWholesale of pharmaceutical and medical goods · NACE 4646Est. 20180 employees
Revenue 2024
NOK 0
EBITDA margin
—
-106% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
NOK -2K
-106% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -2K | -106% |
| Net profit | NOK -2K | -106% |
| Total assets | NOK 29K | -12% |
| Equity | NOK 29K | -7% |
| Employees | 0 | — |
Legal name
NORDIC DIAGNOSTICS AS
Org number
921765665
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. november 2018
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Markedsføring og salg av diagnostisk utstyr og tester innenfor infeksjonsfeltet og alt som naturlig hører med.
Address
H0504 Storgata 61, 4307 Sandnes
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 624 | 1 655 | 275 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −6 | −5 | −2 | −284 | 262 | 37 | −2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −5 | −2 | −284 | 262 | 37 | −2 |
| Net financials | 0 | 0 | 0 | 0 | −1 | 0 | −0 |
| Profit before tax | −6 | −5 | −2 | −284 | 261 | 37 | −2 |
| Tax | −0 | −0 | −0 | −0 | −0 | 0 | −0 |
| Net profit | −6 | −5 | −2 | −284 | 261 | 37 | −2 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 5 004 | 5 001 | 17 | 430 | 72 | 33 | 29 |
| Equity | 24 | 19 | 17 | −266 | −6 | 31 | 29 |
| Long-term debt | 4 980 | 4 982 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 697 | 78 | 2 | 0 |
| Total debt | 4 980 | 4 982 | 0 | 697 | 78 | 2 | 0 |
EBITDA margin
-229800.0%
This company
15.8%
Market median
-1454530% vs market
20182024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182024
Return on equity
-8.0%
This company
18.4%
Market median
-143% vs market
20182024
Net profit margin
-230600.0%
This company
8.1%
Market median
-2847014% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Citron As | Company | 30.0% | 30.0% | 2022 |
Bamsic As | Company | 30.0% | 30.0% | 2022 |
Vidar Arnulf Consulting As | Company | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bamsic As
NORDIC DIAGNOSTICS AS Board members of NORDIC DIAGNOSTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Simen Andre Aarsland Øgreid | Board of Directors | 0 companies |
| Solveig Stråtveit | Board of Directors | 0 companies |
| Dagfinn Steinar Øgreid | Chairman | 0 companies |